Cogent Biosciences Inc (NASDAQ:COGT)

14.33
Delayed Data
As of 4:00pm ET
 -0.59 / -3.95%
Today’s Change
3.79
Today|||52-Week Range
18.07
+67.02%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$979.8M

Company Description

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Contact Information

Cogent Biosciences, Inc.
200 Cambridge Park Drive
Cambridge Massachusetts 02140
P:(617) 945-5576
Investor Relations:

Employees

Shareholders

Other institutional66.37%
Individual stakeholders4.20%
Mutual fund holders31.07%

Top Executives

Andrew R. RobbinsPresident, Chief Executive Officer & Director
John L. GreenChief Financial & Accounting Officer
Jessica SachsChief Medical Officer
John RobinsonChief Scientific Officer
Brad BarnettChief Technology Officer